|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2025―Mar―01 |
Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals |
Amanj Kurdi, Abdulaziz Albutti, Omeed Darweesh, Karwan M. Amen, Kirmanj Baker, Hardee Karwi, Brian Godman |
2 |
[GO] |
2024―Sep―26 |
Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study |
Junjun Xu, Jinmeng Li, Meng Chen, Huifang Jiang, Xudong Fan, Yangmin Hu, et al. (+6) Haili Shan, Mingdong Yang, Yichao Xu, Yuying Lang, Haibin Dai, Xinjun Cai |
3 |
[GO] |
2024―Feb―23 |
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2 |
Ahmad Z. Al Meslamani |
4 |
[GO] |
2023―Oct―06 |
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the omicron era |
Fatima Faraz, Mohammad Ebad Ur Rehman, Abia Shahid, Muhammad Saqib Ghafoor, Huzaifa Ahmad Cheema |
5 |
[GO] |
2023―Feb―02 |
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome? |
Thomas Müller, Peter Riederer, Wilfried Kuhn |
6 |
[GO] |
2022―Dec―03 |
Thrombosis with thrombocytopenia after vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): implications of gender-specific tissue-factor gene polymorphisms? |
Raffaella Mormile |
7 |
[GO] |
2022―Oct―28 |
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect |
Martina Amanzio, Giuseppina Elena Cipriani, Dimos D. Mitsikostas |
8 |
[GO] |
2022―Oct―05 |
Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19 |
Rosanna Ruggiero, Nunzia Balzano, Raffaella Di Napoli, Maria Giuseppa Sullo, Francesco Rossi, Annalisa Capuano, Concetta Rafaniello |
9 |
[GO] |
2022―Sep―01 |
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study |
Raffaele Pellegrino, Gianluca Pellino, Lucio Selvaggi, Francesco Selvaggi, Alessandro Federico, Marco Romano, Antonietta Gerarda Gravina |
10 |
[GO] |
2022―Aug―26 |
The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice |
Vincenzo Russo, Adriano Caputo, Egidio Imbalzano, Pierpaolo Di Micco, Antonio Frontera, Ambra Uccello, et al. (+4) Luana Orlando, Paola Galimberti, Paolo Golino, Antonello D’Andrea |
11 |
[GO] |
2022―Aug―26 |
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics |
Thanaporn Wattanakul, Palang Chotsiri, Ivan Scandale, Richard M. Hoglund, Joel Tarning |
12 |
[GO] |
2022―Aug―01 |
Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect? |
Lyudmila Boyanova, Rumyana Markovska, Ivan Mitov, Raina Gergova |
13 |
[GO] |
2022―Jul―19 |
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials |
Chao-Kun Chen, Teng-Song Weng, Yu-Hung Chen, Jui- Heng Kao, Chien-Ming Chao |
14 |
[GO] |
2022―Jul―02 |
The effect of inhaled corticosteroids on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
Chao-Hsien Chen, Cheng-Yi Wang, Ya-Hui Wang, Ching-Yi Chen, Kuang-Hung Chen, Chih-Cheng Lai, et al. (+2) Yu-Feng Wei, Pin-Kuei Fu |
15 |
[GO] |
2022―Jun―23 |
The impact of the COVID-19 pandemic lockdown measures on the prescribing trends and utilization of opioids in the English primary care setting: segmented-liner regression analysis |
Oula Nawaf Sindi, Faisal Salman Alshaikh, Brian Godman, Amanj Kurdi |
16 |
[GO] |
2022―May―17 |
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Shao-Huan Lan, Chih-Cheng Lai, Shen-Peng Chang, Li-Chin Lu, Shun-Hsing Hung, Wei-Ting Lin |
17 |
[GO] |
2021―Aug―17 |
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients |
Valerio Langella, Roberta Bottino, Antonio Asti, Giulio Maresca, Gisella Di Palma, Domenico Pomponi, et al. (+3) Claudia Sassone, Egidio Imbalzano, Vincenzo Russo |
18 |
[GO] |
2021―Jul―30 |
Vaccination and their importance for lung transplant recipients in a COVID-19 world |
Samantha Scharringa, Thijs Hoffman, Diana A. van Kessel, Ger T. Rijkers |
19 |
[GO] |
2021―Jul―24 |
Molecular docking and dynamics study to explore phytochemical ligand molecules against the main protease of SARS-CoV-2 from extensive phytochemical datasets |
Shafi Mahmud, Mohasana Akter Mita, Suvro Biswas, Gobindo Kumar Paul, Maria Meha Promi, Shamima Afrose, et al. (+7) Robiul Hasan, Sharmin Sultana Shimu, Shahriar Zaman, Salah Uddin, Trina Ekawati Tallei, Talha Bin Emran, Abu Saleh |
20 |
[GO] |
2021―Jun―30 |
Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date |
Grace Kenny, Patrick W. G. Mallon |
21 |
[GO] |
2021―Mar―26 |
Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights |
Ankit Jain, Shiv Kumar Prajapati, Madhavi Tripathi, Ashok M. Raichur, Jagat R. Kanwar |
22 |
[GO] |
2021―Mar―12 |
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: A review of current evidence |
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, Rita Kirton, Frank Kunik |
23 |
[GO] |
2021―Mar―12 |
Compounds of plants with activity against SARS-CoV-2 targets |
Diorge Jônatas Marmitt, Márcia Inês Goettert, Claudete Rempel |
24 |
[GO] |
2021―Mar―08 |
How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic? |
Martina Amanzio, Giuseppina Elena Cipriani, and Massimo Bartoli |
25 |
[GO] |
2021―Feb―18 |
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? |
Harmanjit Singh, Prerna Chauhan, Jasbir Singh, Saurabh Saurabh, CS Gautam, Ashish Kumar Kakkar |
26 |
[GO] |
2021―Jan―27 |
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain |
Esther Chamorro-de-Vega, Carmen-Guadalupe Rodriguez-Gonzalez, Silvia Manrique-Rodríguez, Elena Lobato-Matilla, Felix García-Moreno, Maria Olmedo, et al. (+20) Rafael Correa-Rocha, Maricela Valerio, Teresa Aldámiz-Echevarria, Marina Machado, Milagros Sancho-Gonzalez, Juan Carlos Lopez-Bernaldo-de-Quirós, Paula Ruiz-Briones, Rosa Romero-Jiménez, Camino Sarobe-González, Alvaro Gimenez-Manzorro, Roberto Collado-Borrell, Cecilia M Fernandez-Llamazares, Jose Luis Revuelta-Herrero, Beatriz Somoza-Fernandez, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, Emilio Bouza, Ana Herranz, Patricia Muñoz, Maria Sanjurjo |
27 |
[GO] |
2021―Jan―13 |
SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development |
Chiranjib Chakraborty, Manojit Bhattacharya, Bidyut Mallick, Ashish Ranjan Sharma, Sang-Soo Lee, Govindasamy Agoramoorthy |
28 |
[GO] |
2020―Oct―22 |
Managing blood disorders during the Covid-19 pandemic: current pharmacological insights |
Parathan Karunakaran, Ram Vasudevan Nampoothiri, Kamal Kant Sahu |
29 |
[GO] |
2020―Oct―03 |
Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. |
Shashank Shekhar Gautam, C.S Gautam, Vivek Kumar Garg, Harmanjit Singh |
30 |
[GO] |
2020―Sep―08 |
COVID-19 epidemic: a special focus on diagnosis, complications and management |
Leilei Ai, Liyu Jiang, Zhifei Xu, Hao Yan, Peihua Luo, Qiaojun He |
31 |
[GO] |
2020―Sep―07 |
Melatonin as a putative protection against myocardial injury in COVID-19 infection |
Fedor Simko, Jaroslav Hrenak, Alberto Dominguez-Rodriguez, Russel J. Reiter |
32 |
[GO] |
2020―Aug―14 |
Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches |
Rafael Dal-Ré |
33 |
[GO] |
2020―Aug―04 |
Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges |
Xiaolei Yang, Ye Liu, Yuping Liu, Qing Yang, Xubo Wu, Xuan Huang, et al. (+3) Huijia Liu, Weimin Cai, Guo Ma |
34 |
[GO] |
2020―Jul―30 |
Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs |
Wenyuan Pang, Qiaoyu Wang, Zhigang Zhao |
35 |
[GO] |
2020―Jul―18 |
Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight |
Lucas A D Nicolau, Isabela R S G Nolêto, Jand V R Medeiros |
36 |
[GO] |
2020―Jun―15 |
Contraception and reproductive planning during the COVID-19 pandemic. |
Edson Santos Ferreira-Filho, Nilson Roberto de Melo, Isabel Cristina Esposito Sorpreso, Luis Bahamondes, Ricardo dos Santos Simões, José Maria Soares-Júnior, Edmund Chada Baracat |